Relationship of neurocognitive deficits to diagnosis and symptoms across affective and non-affective psychoses

Schizophrenia Research

Volumn 133, Issue 1-3, 2011, Pages 212-217

  Lewandowski, Kathryn E ^a,b   Cohen, Bruce M ^a,b   Keshavan, Matcheri S ^b,c   Öngür, Dost ^a,b  

^a MCLEAN HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

Bipolar; Comparative; Neurocognitive; Schizoaffective; Schizophrenia

Indexed keywords

ADULT; AFFECTIVE PSYCHOSIS; ARTICLE; BIPOLAR DISORDER; COGNITION; COGNITIVE DEFECT; CONTROLLED STUDY; EXECUTIVE FUNCTION; FEMALE; HUMAN; LINEAR REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; MOOD DISORDER; NEGATIVE SYNDROME; NEUROPSYCHOLOGICAL TEST; OUTCOME ASSESSMENT; PATHOGENESIS; POSITIVE SYNDROME; PREDICTION; PRIORITY JOURNAL; PSYCHIATRIC DIAGNOSIS; SAMPLE; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SYMPTOM;

ADOLESCENT; ADULT; ANALYSIS OF VARIANCE; BIPOLAR DISORDER; COGNITION DISORDERS; FEMALE; HUMANS; MALE; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; PSYCHIATRIC STATUS RATING SCALES; PSYCHOTIC DISORDERS; SCHIZOPHRENIA; YOUNG ADULT;

EID: 81955161945     PISSN: 09209964     EISSN: 15732509     Source Type: Journal    
DOI: 10.1016/j.schres.2011.09.004     Document Type: Article

References (84)

1. Altshuler L.L., Ventura J., van Gorp W.G., Green M.F., Theberge D.C., Mintz J. Neurocognitive function in clinically stable men with bipolar I disorder or schizophrenia and normal control subjects. Biol. Psychiatry 2004, 56:560-569.
2. Alves Fda S., Figee M., Vamelsvoort T., Veltman D., de Haan L. The revised dopamine hypothesis of schizophrenia: evidence from pharmacological MRI studies with atypical antipsychotic medication. Psychopharmacol. Bull. 2008, 41:121-132.
3. Andreasen N.C., Flaum M., Swayze V.W., Tyrrell G., Arndt S. Positive and negative symptoms in schizophrenia. A critical reappraisal. Arch. Gen. Psychiatry 1990, 47:615-621.
4. Balanza-Martinez V., Tabares-Seisdedos R., Selva-Vera G., Martinez-Aran A., Torrent C., Salazar-Fraile J., Leal-Cercos C., Vieta E., Gomez-Beneyto M. Persistent cognitive dysfunctions in bipolar I disorder and schizophrenic patients: a 3-year follow-up study. Psychother. Psychosom. 2005, 74:113-119.
5. Balanza-Martinez V., Selva G., Martinez-Aran A., Prickaerts J., Salazar J., Gonzalez-Pinto A., Vieta E., Tabares-Seisdedos R. Neurocognition in bipolar disorders - a closer look at comorbidities and medications. Eur. J. Pharmacol. 2010, 626:87-96.
6. Barch D.M. Neuropsychological abnormalities in schizophrenia and major mood disorders: similarities and differences. Curr. Psychiatry Rep. 2009, 11:313-319.
7. Bell M., Fiszdon J., Greig T., Wexler B., Bryson G. Neurocognitive enhancement therapy with work therapy in schizophrenia: 6-month follow-up of neuropsychological performance. J. Rehabil. Res. Dev. 2007, 44:761-770.
8. Bell M.D., Zito W., Greig T., Wexler B.E. Neurocognitive enhancement therapy with vocational services: work outcomes at two-year follow-up. Schizophr. Res. 2008, 105:18-29.
9. Benedict R.H. Brief Visuospatial Memory Test-Revised 1997, Psychological Assessment Resources, Inc, Odessa, FL.
10. Benedict R.H.B., Schretlen D., Groninger L., Brandt J. Hopkins Verbal Learning Test-Revised: normative data and analysis of inter-form and test-retest reliability. Clin. Neuropsychol. 1998, 12:43-55.
11. Berman I., Viegner B., Merson A., Allan E., Pappas D., Green A.I. Differential relationships between positive and negative symptoms and neuropsychological deficits in schizophrenia. Schizophr. Res. 1997, 25:1-10.
12. Bowie C.R., Depp C., McGrath J.A., Wolyniec P., Mausbach B.T., Thornquist M.H., Luke J., Patterson T.L., Harvey P.D., Pulver A.E. Prediction of real-world functional disability in chronic mental disorders: a comparison of schizophrenia and bipolar disorder. Am. J. Psychiatry 2010, 167:1116-1124.
13. Brazo P., Marie R.M., Halbecq I., Benali K., Segard L., Delamillieure P., Langlois-Thery S., Van Der Elst A., Thibaut F., Petit M., Dollfus S. Cognitive patterns in subtypes of schizophrenia. Eur. Psychiatry 2002, 17:155-162.
14. Craddock N., Owen M.J. Rethinking psychosis: the disadvantages of a dichotomous classification now outweigh the advantages. World Psychiatry 2007, 6:84-91.
15. Craddock N., O'Donovan M.C., Owen M.J. Genes for schizophrenia and bipolar disorder? Implications for psychiatric nosology. Schizophr. Bull. 2006, 32:9-16.
16. Cvetic T., Vukovic O. Cognitive deficit in schizophrenia: comparative analysis of positive and negative subtype and predictors of positive subtype. Psychiatr. Danub. 2006, 18:4-11.
17. Daban C., Martinez-Aran A., Torrent C., Tabares-Seisdedos R., Balanza-Martinez V., Salazar-Fraile J., Selva-Vera G., Vieta E. Specificity of cognitive deficits in bipolar disorder versus schizophrenia. A systematic review. Psychother. Psychosom. 2006, 75:72-84.
18. Dixon T., Kravariti E., Frith C., Murray R.M., McGuire P.K. Effect of symptoms on executive function in bipolar illness. Psychol. Med. 2004, 34:811-821.
19. Dominguez Mde G., Veichtbauer W., Simons C.J., van Os J., Krabbendam L. Are psychotic psychopathology and neurocognition orthogonal? A systematic review of their associations. Psychol. Bull. 2009, 135:157-171.
20. Donaldson S., Goldstein L.H., Landau S., Raymont V., Frangou S. The Maudsley Bipolar Disorder Project: the effect of medication, family history, and duration of illness on IQ and memory in bipolar I disorder. J. Clin. Psychiatry 2003, 64:86-93.
21. Eack S.M., Greenwald D.P., Hogarty S.S., Cooley S.J., DiBarry A.L., Montrose D.M., Keshavan M.S. Cognitive enhancement therapy for early-course schizophrenia: effects of a two-year randomized controlled trial. Psychiatr. Serv. 2009, 60:1468-1476.
22. Elie D., Poirier M., Chianetta J., Durand M., Gregoire C., Grignon S. Cognitive effects of antipsychotic dosage and polypharmacy: a study with the BACS in patients with schizophrenia and schizoaffective disorder. J. Psychopharmacol. 2010, 24(7):37-44.
23. First M.B., Spitzer R.L., Gibbon M., Williams J.B.W. Structured Clinical Interview for DSM-IV Axis I Disorders, Clinician Version (SCID-CV) 1996, American Psychiatric Press, Inc., Washington, DC.
24. Fisher M., Holland C., Subramaniam K., Vinogradov S. Neuroplasticity-based cognitive training in schizophrenia: an interim report on the effects 6 months later. Schizophr. Bull. 2010, 36(4):869-879.
25. Gardner D.M., Murphy A.L., O'Donnell H., Centorrino F., Baldessarini R.J. International consensus study of antipsychotic dosing. Am. J. Psychiatry 2010, 167:686-693.
26. Gladsjo J.A., Schuman C.C., Evans J.D., Peavy G.M., Miller S.W., Heaton R.K. Norms for letter and category fluency: demographic corrections for age, education, and ethnicity. Assessment 1999, 6:147-178.
27. Glahn D.C., Bearden C.E., Cakir S., Barrett J.A., Najt P., Serap Monkul E., Maples N., Velligan D.I., Soares J.C. Differential working memory impairment in bipolar disorder and schizophrenia: effects of lifetime history of psychosis. Bipolar Disord. 2006, 8:117-123.
28. Glahn D.C., Bearden C.E., Barguil M., Barrett J., Reichenberg A., Bowden C.L., Soares J.C., Velligan D.I. The neurocognitive signature of psychotic bipolar disorder. Biol. Psychiatry 2007, 62:910-916.
29. Golden C.J. Stroop Color and Word Test 1978, Stoelting Company, Chicago, IL.
30. Goldman-Rakic P.S., Selemon L.D. Functional and anatomical aspects of prefrontal pathology in schizophrenia. Schizophr. Bull. 1997, 23:437-458.
31. Green M. What are the functional consequences of neurocognitive deficits in schizophrenia?. Am. J. Psychiatry 1996, 153:321-330.
32. Green M.F. Cognitive impairment and functional outcome in schizophrenia and bipolar disorder. J. Clin. Psychiatry 2006, 67:e12.
33. Gruber S.A., Rosso I.M., Yurgelun-Todd D. Neuropsychological performance predicts clinical recovery in bipolar patients. J. Affect. Disord. 2008, 105:253-260.
34. Harvey P.D., Keefe R.S. Studies of cognitive change in patients with schizophrenia following novel antipsychotic treatment. Am. J. Psychiatry 2001, 158:176-184.
35. Harvey P.D., Keefe R.S., Moskowitz J., Putnam K.M., Mohs R.C., Davis K.L. Attentional markers of vulnerability to schizophrenia: performance of medicated and unmedicated patients and normals. Psychiatry Res. 1990, 33:179-188.
36. Heinrichs R.W., Ammari N., McDermid Vaz S., Miles A.A. Are schizophrenia and schizoaffective disorder neuropsychologically distinguishable?. Schizophr. Res. 2008, 99:149-154.
37. Hill S.K., Ragland J.D., Gur R.C., Gur R.E. Neuropsychological differences among empirically derived clinical subtypes of schizophrenia. Neuropsychology 2001, 15:492-501.
38. Insel T., Cuthbert B., Garvey M., Heinssen R., Pine D.S., Quinn K., Sanislow C., Wang P. Research domain criteria (RDoC): toward a new classification framework for research on mental disorders. Am. J. Psychiatry 2010, 167:748-751.
39. Kay S.R., Fiszbein A., Opler L.A. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr. Bull. 1987, 13:261-276.
40. Keefe R.S., Bilder R.M., Davis S.M., Harvey P.D., Palmer B.W., Gold J.M., Meltzer H.Y., Green M.F., Capuano G., Stroup T.S., McEvoy J.P., Swartz M.S., Rosenheck R.A., Perkins D.O., Davis C.E., Hsiao J.K., Lieberman J.A. Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial. Arch. Gen. Psychiatry 2007, 64:633-647.
41. Kendler K.S., Karkowski L.M., Walsh D. The structure of psychosis: latent class analysis of probands from the Roscommon Family Study. Arch. Gen. Psychiatry 1998, 55:492-499.
42. Knable M.B., Weinberger D.R. Dopamine, the prefrontal cortex and schizophrenia. J. Psychopharmacol. (Oxf) 1997, 11:123-131.
43. Krabbendam L., Arts B., van Os J., Aleman A. Cognitive functioning in patients with schizophrenia and bipolar disorder: a quantitative review. Schizophr. Res. 2005, 80:137-149.
44. Kurtz M.M., Seltzer J.C., Shagan D.S., Thime W.R., Wexler B.E. Computer-assisted cognitive remediation in schizophrenia: what is the active ingredient?. Schizophr. Res. 2007, 89:251-260.
45. Leeson V.C., Barnes T.R., Hutton S.B., Ron M.A., Joyce E.M. IQ as a predictor of functional outcome in schizophrenia: a longitudinal, four-year study of first-episode psychosis. Schizophr. Res. 2009, 107:55-60.
46. Lehman A.F., Steinwachs D.M. Translating research into practice: the Schizophrenia Patient Outcomes Research Team (PORT) treatment recommendations. Schizophr. Bull. 1998, 24:1-10.
47. Lewandowski K.E., Cohen B.M., Ongur D. Evolution of neuropsychological dysfunction during the course of schizophrenia and bipolar disorder. Psychol. Med. 2011, 41(2):225-241.
48. Lewandowski K.E., Eack S.M., Hogarty S.S., Greenwald D.P., Keshavan M.S. Is cognitive enhancement therapy equally effective for patients with schizophrenia and schizoaffective disorder?. Schizophr. Res. 2011, 125:291-294.
49. Martinez-Aran A., Torrent C., Tabares-Seisdedos R., Salamero M., Daban C., Balanza-Martinez V., Sanchez-Moreno J., Manuel Goikolea J., Benabarre A., Colom F., Vieta E. Neurocognitive impairment in bipolar patients with and without history of psychosis. J. Clin. Psychiatry 2008, 69:233-239.
50. Martino D.J., Marengo E., Igoa A., Scapola M., Ais E.D., Perinot L., Strejilevich S.A. Neurocognitive and symptomatic predictors of functional outcome in bipolar disorders: a prospective 1 year follow-up study. J. Affect. Disord. 2009, 116:37-42.
51. McClellan J., Prezbindowski A., Breiger D., McCurry C. Neuropsychological functioning in early onset psychotic disorders. Schizophr. Res. 2004, 68:21-26.
52. McGrath J., Scheldt S., Welham J., Clair A. Performance on tests sensitive to impaired executive ability in schizophrenia, mania and well controls: acute and subacute phases. Schizophr. Res. 1997, 26:127-137.
53. McGurk S.R., Wykes T. Cognitive remediation and vocational rehabilitation. Psychiatr. Rehabil. J. 2008, 31:350-359.
54. Medalia A., Choi J. Cognitive remediation in schizophrenia. Neuropsychol. Rev. 2009, 19:353-364.
55. Mojtabai R., Bromet E.J., Harvey P.D., Carlson G.A., Craig T.J., Fennig S. Neuropsychological differences between first-admission schizophrenia and psychotic affective disorders. Am. J. Psychiatry 2000, 157:1453-1460.
56. Montgomery S., Asberg M. A new depression scale designed to be sensitive to change. Br. J. Psychiatry 1979, 134:382-389.
57. Morice R. Cognitive inflexibility and pre-frontal dysfunction in schizophrenia and mania. Br. J. Psychiatry 1990, 157:50-54.
58. Nieuwenstein M.R., Aleman A., de Haan E.H. Relationship between symptom dimensions and neurocognitive functioning in schizophrenia: a meta-analysis of WCST and CPT studies. Wisconsin Card Sorting Test. Continuous Performance Test. J. Psychiatr. Res. 2001, 35:119-125.
59. Osuji I.J., Cullum C.M. Cognition in bipolar disorder. Psychiatr. Clin. North Am. 2005, 28:427-441.
60. Reichenberg A., Harvey P.D., Bowie C.R., Mojtabai R., Rabinowitz J., Heaton R.K., Bromet E. Neuropsychological function and dysfunction in schizophrenia and psychotic affective disorders. Schizophr. Bull. 2008, 35:1022-1029.
61. Reichenberg A., Harvey P.D., Bowie C.R., Mojtabai R., Rabinowitz J., Heaton R.K., Bromet E. Neuropsychological function and dysfunction in schizophrenia and psychotic affective disorders. Schizophr. Bull. 2009, 35:1022-1029.
62. Sanchez-Morla E.M., Barabash A., Martinez-Vizcaino V., Tabares-Seisdedos R., Balanza-Martinez V., Cabranes-Diaz J.A., Baca-Baldomero E., Gomez J.L. Comparative study of neurocognitive function in euthymic bipolar patients and stabilized schizophrenic patients. Psychiatry Res. 2009, 169:220-228.
63. Schretlen D.J., Cascella N.G., Meyer S.M., Kingery L.R., Testa S.M., Munro C.A., Pulver A.E., Rivkin P., Rao V.A., Diaz-Asper C.M., Dickerson F.B., Yolken R.H., Pearlson G.D. Neuropsychological functioning in bipolar disorder and schizophrenia. Biol. Psychiatry 2007, 62:179-186.
64. Selnes O.A., Jacobson L., Machado A.M., Becker J.T., Wesch J., Miller E.N., Visscher B., McArthur J.C. Normative data for a brief neuropsychological screening battery. Multicenter AIDS Cohort Study. Percept. Mot. Skills 1991, 73:539-550.
65. Selva G., Salazar J., Balanza-Martinez V., Martinez-Aran A., Rubio C., Daban C., Sanchez-Moreno J., Vieta E., Tabares-Seisdedos R. Bipolar I patients with and without a history of psychotic symptoms: do they differ in their cognitive functioning?. J. Psychiatr. Res. 2007, 41:265-272.
66. Simonsen C., Sundet K., Vaskinn A., Birkenaes A.B., Engh J.A., Faerden A., Jonsdottir H., Ringen P.A., Opjordsmoen S., Melle I., Friis S., Andreassen O.A. Neurocognitive dysfunction in bipolar and schizophrenia spectrum disorders depends on history of psychosis rather than diagnostic group. Schizophr. Bull. 2011, 37(1):73-83.
67. Smith M.J., Barch D.M., Csernansky J.G. Bridging the gap between schizophrenia and psychotic mood disorders: Relating neurocognitive deficits to psychopathology. Schizophr. Res. 2009, 107:69-75.
68. Stip E., Dufresne J., Lussier I., Yatham L. A double-blind, placebo-controlled study of the effects of lithium on cognition in healthy subjects: mild and selective effects on learning. J. Affect. Disord. 2000, 60:147-157.
69. Stip E., Sepehry A.A., Prouteau A., Briand C., Nicole L., Lalonde P., Lesage A. Cognitive discernible factors between schizophrenia and schizoaffective disorder. Brain Cogn. 2005, 59:292-295.
70. Sweeney J.A., Kmiec J.A., Kupfer D.J. Neuropsychologic impairments in bipolar and unipolar mood disorders on the CANTAB neurocognitive battery. Biol. Psychiatry 2000, 48:674-684.
71. Szoke A., Meary A., Trandafir A., Bellivier F., Roy I., Schurhoff F., Leboyer M. Executive deficits in psychotic and bipolar disorders - implications for our understanding of schizoaffective disorder. Eur. Psychiatry 2008, 23:20-25.
72. Tabares-Seisdedos R., Balanza-Martinez V., Sanchez-Moreno J., Martinez-Aran A., Salazar-Fraile J., Selva-Vera G., Rubio C., Mata I., Gomez-Beneyto M., Vieta E. Neurocognitive and clinical predictors of functional outcome in patients with schizophrenia and bipolar I disorder at one-year follow-up. J. Affect. Disord. 2008, 109:286-299.
73. Tam W.C., Liu Z. Comparison of neurocognition between drug-free patients with schizophrenia and bipolar disorder. J. Nerv. Ment. Dis. 2004, 192:464-470.
74. Toomey R., Faraone S.V., Simpson J.C., Tsuang M.T. Negative, positive, and disorganized symptoms dimensions in schizophrenia, major depression, and bipolar disorder. J. Nerv. Ment. Dis. 1998, 186:470-476.
75. Torrey E.F. Epidemiological comparison of schizophrenia and bipolar disorder. Schizophr. Res. 1999, 39:101-106. Discussion 159-160.
76. Tsuang M.T., Winokur G., Crowe R.R. Morbidity risks of schizophrenia and affective disorders among first degree relatives of patients with schizophrenia, mania, depression and surgical conditions. Br. J. Psychiatry 1980, 137:497-504.
77. Valles V., Van Os J., Guillamat R., Gutierrez B., Campillo M., Gento P., Fananas L. Increased morbid risk for schizophrenia in families of in-patients with bipolar illness. Schizophr. Res. 2000, 42:83-90.
78. Wang X., Yao S., Kirkpatrick B., Shi C., Yi J. Psychopathology and neuropsychological impairments in deficit and nondeficit schizophrenia of Chinese origin. Psychiatry Res. 2008, 158:195-205.
79. Wingo A.P., Wingo T.S., Harvey P.D., Baldessarini R.J. Effects of lithium on cognitive performance: a meta-analysis. J. Clin. Psychiatry 2009, 626:87-96.
80. Woods S.W. Chlorpromazine equivalent doses for the newer atypical antipsychotics. J. Clin. Psychiatry 2003, 64:663-667.
81. Woodward N.D., Purdon S.E., Meltzer H.Y., Zald D.H. A meta-analysis of neuropsychological change to clozapine, olanzapine, quetiapine, and risperidone in schizophrenia. Int. J. Neuropsychopharmacol. 2005, 8:457-472.
82. Wykes T. Review: cognitive remediation improves cognitive functioning in schizophrenia. Evid. Based Ment. Health 2008, 11:117.
83. Young R.C., Biggs J.T., Ziegler V.E., Meyer D.A. A rating scale for mania: reliability, validity and sensitivity. Br. J. Psychiatry 1978, 133:429-435.
84. Zalewski C., Johnson-Selfridge M.T., Ohriner S., Zarrella K., Seltzer J.C. A review of neuropsychological differences between paranoid and nonparanoid schizophrenia patients. Schizophr. Bull. 1998, 24:127-145.